Research programme: cannabinoid prodrugs - Vitality Biopharma

Drug Profile

Research programme: cannabinoid prodrugs - Vitality Biopharma

Alternative Names: Cannabinoid glycosides - Vitality Biopharma; Cannabinosides - Vitality Biopharma

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Vitality Biopharma
  • Class Antiepileptic drugs; Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epilepsy; Guillain-Barre syndrome; Huntington's disease; Inflammatory bowel diseases; Pain; Schizophrenia

Most Recent Events

  • 16 Nov 2016 Early research in Pain (narcotic bowel syndrome) in USA
  • 09 Nov 2016 Vitality files for patent protection with The Patent Cooperation Treaty (PCT) for cannabinoid prodrugs
  • 14 Sep 2016 Preclinical trials in Inflammatory bowel disease in USA (IV) prior to September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top